Core Viewpoint - Baixinan-B (02185) experienced a significant stock price increase, rising nearly 15% at the close, with a current price of 6.14 HKD and a trading volume of 16.9358 million HKD, indicating strong market interest and potential growth opportunities in the medical device sector [1] Company Developments - Bluefan Medical (002382) announced a strategic partnership with Baixinan for the Iberis multi-polar renal denervation (RDN) system, leveraging its platform capabilities and industry reputation to expand into international markets [1] - The Iberis RDN system has achieved commercialization in Germany, Spain, and Italy, with Germany and France including it in their healthcare insurance coverage, enhancing its market accessibility [1] - The system has recently received approval from the Singapore Health Sciences Authority for clinical use, marking a significant milestone in its international rollout [1] Market Potential - According to Zhi Shi Consulting, the annual market size for RDN in China is expected to exceed 10 billion RMB by 2032, highlighting the growth potential in this therapeutic area [1] - Huafu Securities noted that the Baixinan Iberis RDN system is the only one globally approved for both transradial (TRA) and transfemoral access routes, providing a significant first-mover advantage in the market [1] - The collaboration with Yuanda Health and various international partners is expected to accelerate Baixinan's commercialization efforts, positioning the company favorably in the competitive landscape [1]
百心安-B尾盘涨近15% RDN赛道迎来商业化放量新阶段 公司全球商业化有望加速